Teva Pharmaceuticals announced that the FDA approved QVAR RediHaler inhalation aerosol for the prophylactic treatment of asthma in patients aged older than 4 years, according to a company press ...

Qvar RediHaler (beclomethasone dipropionate HFA) Inhalation Aerosol is a breath-actuated inhaled prescription medicine used as a maintenance treatment for the prevention and control of asthma in ...

Study reveals that patients treated with QVAR had a similar or better chance of achieving asthma control at lower prescribed doses than with fluticasone HORSHAM, Pa., Sept. 8 /PRNewswire/ -- Teva ...

Jerusalem, May 18, 2014 – Teva Pharmaceutical Industries Ltd., (NYSE: TEVA) today announced that results from a real-life, retrospective, observational study of QVAR® will be presented at the American ...

Oct 27 (Reuters) - Teva Pharmaceuticals has agreed to pay $35 million and withdraw six patents from a U.S. regulatory list to settle claims that the drugmaker delayed generic competition for its QVAR ...

First and Only Breath-Actuated Aerosol Inhaled Corticosteroid in the United States Designed to Help Eliminate the Need for Hand-Breath Coordination JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical ...

Teva announced that the FDA has approved Qvar (beclomethasone dipropionate HFA) with a dose counter for the ongoing treatment of asthma as a preventative therapy in patients ≥5 years of age. In 2003, ...

JERUSALEM — Teva Pharmaceutical on Friday announced that the Food and Drug Administration approved the use of QVAR (beclomethasone dipropionate HFA) with a dose counter for the treatment of asthma in ...

Objective: To assess the bioequivalence of beclomethasone dipropionate (BDP) delivered from a press-and-breathe (PB) inhaler and a breath-actuated inhaler (Autohaler TM, AH). Design: Two randomised, ...

The efficacy of inhaled steroids in spontaneously breathing infants with established bronchopulmonary dysplasia (BPD) is debatable. The inhaled steroid hydrofluoalkane-beclomethasone dipropionate ...

* Teva Pharmaceutical Industries Ltd - plans to discontinue sales of this current QVAR MDI formulation upon launch of qvarredihaler in Q1 of 2018 * Teva Pharmaceutical Industries - QVAR redihaler ...

MIAMI--(BUSINESS WIRE)--Oct. 1, 2003--IVAX Corporation (AMEX:IVX) (LSE:IVX.L) has completed its previously announced agreement with the 3M Company (NYSE:MMM) in which IVAX assumes exclusive rights to ...